Evidence map›Paper›PMID 37924278›Full record

ArticleHealth technology assessment (Winchester, England)2023

Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.

Nadeem Qureshi, Bethan Woods, Rita Neves de Faria, Pedro Saramago Goncalves, Edward Cox, Jo Leonardi Bee, Laura Condon, Stephen Weng, Ralph K Akyea, Barbara Iyen and 10 more

Abstract read
In one paragraph

Article in Health technology assessment (Winchester, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nadeem QureshiPRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0003-4909-0644
Bethan WoodsCentre for Health Economics, University of York, York, UK.ORCID 0000-0002-7669-9415
Rita Neves de FariaCentre for Health Economics, University of York, York, UK.ORCID 0000-0003-3410-1435
Pedro Saramago GoncalvesCentre for Health Economics, University of York, York, UK.ORCID 0000-0001-9063-8590
Edward CoxCentre for Health Economics, University of York, York, UK.ORCID 0000-0001-8981-0699
Jo Leonardi BeePRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0003-0893-6068
Laura CondonPRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-7039-3095
Stephen WengCardiovascular and Metabolism, Janssen Research and Development, High Wycombe, UK.ORCID 0000-0002-5281-9590
Ralph K AkyeaPRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0003-4529-8237
Barbara IyenPRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0001-9720-1180
Paul RoderickPrimary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK.ORCID 0000-0001-9475-6850
Steve E HumphriesCentre for Cardiovascular Genetics, Institute for Cardiovascular Science, University College London, London, UK.ORCID 0000-0002-8221-6547
William RowlandsPatient representative.ORCID 0000-0001-5107-7292
Melanie WatsonWessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Southampton, UK.ORCID 0000-0002-5140-4086
Kate HaralambosFamilial Hypercholesterolaemia Service, University Hospital of Wales, Cardiff, UK.ORCID 0000-0001-6075-3125
Ryan KennyPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-9743-4259
Dev DattaLipid Unit, University Hospital Llandough, Penarth, UK.ORCID 0000-0001-7856-7363
Zosia MiedzybrodzkaDivision of Applied Medicine, University of Aberdeen, Aberdeen, UK.ORCID 0000-0003-2890-8136
Christopher ByrneSouthampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.ORCID 0000-0001-6322-7753
Joe KaiPRISM Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0001-9040-9384

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cascade testing the relatives of people with familial hypercholesterolaemia is an efficient approach to identifying familial hypercholesterolaemia. The cascade-testing protocol starts with identifying an index patient with familial hypercholesterolaemia, followed by one of three approaches to contact other relatives: indirect approach, whereby index patients contact their relatives; direct approach, whereby the specialist contacts the relatives; or a combination of both direct and indirect approaches. However, it is unclear which protocol may be most effective. Objectives: The objectives were to determine the yield of cases from different cascade-testing protocols, treatment patterns, and short- and long-term outcomes for people with familial hypercholesterolaemia; to evaluate the cost-effectiveness of alternative protocols for familial hypercholesterolaemia cascade testing; and to qualitatively assess the acceptability of different cascade-testing protocols to individuals and families with familial hypercholesterolaemia, and to health-care providers. Design and methods: This study comprised systematic reviews and analysis of three data sets: PASS (PASS Software, Rijswijk, the Netherlands) hospital familial hypercholesterolaemia databases, the Clinical Practice Research Datalink (CPRD)-Hospital Episode Statistics (HES) linked primary-secondary care data set, and a specialist familial hypercholesterolaemia register. Cost-effectiveness modelling, incorporating preceding analyses, was undertaken. Acceptability was examined in interviews with patients, relatives and health-care professionals. Result: Systematic review of protocols: based on data from 4 of the 24 studies, the combined approach led to a slightly higher yield of relatives tested [40%, 95% confidence interval (CI) 37% to 42%] than the direct (33%, 95% CI 28% to 39%) or indirect approaches alone (34%, 95% CI 30% to 37%). The PASS databases identified that those contacted directly were more likely to complete cascade testing ( Limitations: Systematic reviews were not used in the economic analysis, as relevant studies were lacking or of poor quality. As only a proportion of those with primary care-coded familial hypercholesterolaemia are likely to actually have familial hypercholesterolaemia, CPRD analyses are likely to underestimate the true effect. The cost-effectiveness analysis required assumptions related to the long-term cardiovascular disease risk, the effect of treatment on cholesterol and the generalisability of estimates from the data sets. Interview recruitment was limited to white English-speaking participants. Conclusions: Based on limited evidence, most cost-effective cascade-testing protocols, diagnosing most relatives, select index cases by genetic testing, with services directly contacting relatives, and contacting second-degree relatives even if first-degree relatives have not been tested. Combined approaches to contact relatives may be more suitable for some families. Future work: Establish a long-term familial hypercholesterolaemia cohort, measuring cholesterol levels, treatment and cardiovascular outcomes. Conduct a randomised study comparing different approaches to contact relatives. Study registration: This study is registered as PROSPERO CRD42018117445 and CRD42019125775. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in

Indexed as

Cardiovascular DiseasesHyperlipoproteinemia Type IICholesterolCost-Benefit AnalysisCost-Effectiveness AnalysisHumansSystematic Reviews as TopicCholesterolCARDIOVASCULAR DISEASESCHOLESTEROLGENETIC TESTINGHEART DISEASE RISK FACTORSHYPERCHOLESTEROLAEMIAHYPERLIPOPROTEINEMIA TYPE IIPEDIGREE

Identifiers

PMID37924278
PMCPMC10658348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.